AAPL324.53-0.61 (-0.19%) ▼|ABBV258.72-1.27 (-0.49%) ▼|ABT112.09+3.16 (+2.90%) ▲|ACN186.16-1.93 (-1.03%) ▼|ADBE282.68-3.41 (-1.19%) ▼|AMAT437.13-4.73 (-1.07%) ▼|AMD457.95-1.66 (-0.36%) ▼|AMGN437.01-1.11 (-0.25%) ▼|AMT174.30-1.72 (-0.98%) ▼|AMZN255.10+0.18 (+0.07%) ▲|AVGO369.77+0.09 (+0.02%) ▲|AXP329.95+5.76 (+1.78%) ▲|BA210.00+4.34 (+2.11%) ▲|BAC63.18+1.19 (+1.91%) ▲|BKNG198.67+2.98 (+1.52%) ▲|BLK1,123.43-4.67 (-0.41%) ▼|BMY67.06+0.14 (+0.21%) ▲|BNY161.84+1.33 (+0.83%) ▲|BRK-B507.73+5.40 (+1.08%) ▲|C134.93+2.39 (+1.80%) ▲|CAT785.34+6.18 (+0.79%) ▲|CL90.45+0.82 (+0.91%) ▲|CMCSA27.06+0.76 (+2.89%) ▲|COF218.64+7.30 (+3.45%) ▲|COP136.28+0.09 (+0.07%) ▲|COST934.82-5.14 (-0.55%) ▼|CRM255.33-2.79 (-1.08%) ▼|CSCO109.01-0.73 (-0.67%) ▼|CVS98.41+0.81 (+0.83%) ▲|CVX211.71+0.66 (+0.31%) ▲|DE686.10+10.02 (+1.48%) ▲|DHR210.09+3.16 (+1.52%) ▲|DIS108.68+2.46 (+2.31%) ▲|DUK120.34-0.05 (-0.04%) ▼|EMR149.61+1.98 (+1.34%) ▲|FDX322.30-2.58 (-0.79%) ▼|GD363.41-6.01 (-1.63%) ▼|GE332.17+1.08 (+0.33%) ▲|GEV901.08+2.55 (+0.28%) ▲|GILD150.10+0.18 (+0.12%) ▲|GM85.09-0.54 (-0.63%) ▼|GOOG333.66+1.63 (+0.49%) ▲|GOOGL337.29+2.27 (+0.68%) ▲|GS1,007.58+5.02 (+0.50%) ▲|HD320.31+0.54 (+0.17%) ▲|HON208.39-1.59 (-0.76%) ▼|IBM230.57-0.83 (-0.36%) ▼|INTC89.54+0.57 (+0.64%) ▲|INTU343.17-1.77 (-0.51%) ▼|ISRG380.16+10.91 (+2.95%) ▲|JNJ274.41+3.22 (+1.19%) ▲|JPM358.82+3.87 (+1.09%) ▲|KO88.78+0.78 (+0.89%) ▲|LIN488.69+1.93 (+0.40%) ▲|LLY1,174.01+14.01 (+1.21%) ▲|LMT533.01-11.50 (-2.11%) ▼|LOW201.48+1.43 (+0.71%) ▲|LRCX287.10-3.10 (-1.07%) ▼|MA589.42+8.32 (+1.43%) ▲|MCD262.52+1.41 (+0.54%) ▲|MDLZ62.37+0.76 (+1.23%) ▲|MDT94.26+2.22 (+2.41%) ▲|META595.84+17.30 (+2.99%) ▲|MMM169.96-0.28 (-0.17%) ▼|MO69.49-0.08 (-0.12%) ▼|MRK150.63+0.77 (+0.51%) ▲|MS213.63+2.59 (+1.23%) ▲|MSFT497.62-3.40 (-0.68%) ▼|MU940.77+7.33 (+0.78%) ▲|NEE82.77-0.16 (-0.19%) ▼|NFLX82.68+1.87 (+2.31%) ▲|NKE38.48+0.36 (+0.94%) ▲|NOW138.12-4.78 (-3.35%) ▼|NVDA226.23+8.79 (+4.04%) ▲|ORCL145.44+4.12 (+2.92%) ▲|PEP141.48+1.69 (+1.21%) ▲|PFE28.86+0.31 (+1.07%) ▲|PG147.58+1.37 (+0.94%) ▲|PLTR170.04-9.88 (-5.49%) ▼|PM188.16+1.01 (+0.54%) ▲|QCOM169.42+2.81 (+1.69%) ▲|RTX202.29-2.87 (-1.40%) ▼|SBUX107.60+1.45 (+1.37%) ▲|SCHW109.43+1.15 (+1.06%) ▲|SO88.02-0.07 (-0.08%) ▼|SPG210.21-1.66 (-0.78%) ▼|T26.36+0.36 (+1.37%) ▲|TMO607.30+6.80 (+1.13%) ▲|TMUS187.48+5.32 (+2.92%) ▲|TSLA355.30-0.79 (-0.22%) ▼|TXN256.70+3.36 (+1.32%) ▲|UBER76.60+1.36 (+1.80%) ▲|UNH400.09+3.79 (+0.96%) ▲|UNP290.67+0.05 (+0.02%) ▲|UPS103.26+0.60 (+0.58%) ▲|USB62.60+1.39 (+2.26%) ▲|V379.26+6.59 (+1.77%) ▲|VZ50.69+0.39 (+0.77%) ▲|WFC89.67+2.63 (+3.02%) ▲|WMT106.05+0.13 (+0.12%) ▲|XOM163.07-1.49 (-0.90%) ▼|AAPL324.53-0.61 (-0.19%) ▼|ABBV258.72-1.27 (-0.49%) ▼|ABT112.09+3.16 (+2.90%) ▲|ACN186.16-1.93 (-1.03%) ▼|ADBE282.68-3.41 (-1.19%) ▼|AMAT437.13-4.73 (-1.07%) ▼|AMD457.95-1.66 (-0.36%) ▼|AMGN437.01-1.11 (-0.25%) ▼|AMT174.30-1.72 (-0.98%) ▼|AMZN255.10+0.18 (+0.07%) ▲|AVGO369.77+0.09 (+0.02%) ▲|AXP329.95+5.76 (+1.78%) ▲|BA210.00+4.34 (+2.11%) ▲|BAC63.18+1.19 (+1.91%) ▲|BKNG198.67+2.98 (+1.52%) ▲|BLK1,123.43-4.67 (-0.41%) ▼|BMY67.06+0.14 (+0.21%) ▲|BNY161.84+1.33 (+0.83%) ▲|BRK-B507.73+5.40 (+1.08%) ▲|C134.93+2.39 (+1.80%) ▲|CAT785.34+6.18 (+0.79%) ▲|CL90.45+0.82 (+0.91%) ▲|CMCSA27.06+0.76 (+2.89%) ▲|COF218.64+7.30 (+3.45%) ▲|COP136.28+0.09 (+0.07%) ▲|COST934.82-5.14 (-0.55%) ▼|CRM255.33-2.79 (-1.08%) ▼|CSCO109.01-0.73 (-0.67%) ▼|CVS98.41+0.81 (+0.83%) ▲|CVX211.71+0.66 (+0.31%) ▲|DE686.10+10.02 (+1.48%) ▲|DHR210.09+3.16 (+1.52%) ▲|DIS108.68+2.46 (+2.31%) ▲|DUK120.34-0.05 (-0.04%) ▼|EMR149.61+1.98 (+1.34%) ▲|FDX322.30-2.58 (-0.79%) ▼|GD363.41-6.01 (-1.63%) ▼|GE332.17+1.08 (+0.33%) ▲|GEV901.08+2.55 (+0.28%) ▲|GILD150.10+0.18 (+0.12%) ▲|GM85.09-0.54 (-0.63%) ▼|GOOG333.66+1.63 (+0.49%) ▲|GOOGL337.29+2.27 (+0.68%) ▲|GS1,007.58+5.02 (+0.50%) ▲|HD320.31+0.54 (+0.17%) ▲|HON208.39-1.59 (-0.76%) ▼|IBM230.57-0.83 (-0.36%) ▼|INTC89.54+0.57 (+0.64%) ▲|INTU343.17-1.77 (-0.51%) ▼|ISRG380.16+10.91 (+2.95%) ▲|JNJ274.41+3.22 (+1.19%) ▲|JPM358.82+3.87 (+1.09%) ▲|KO88.78+0.78 (+0.89%) ▲|LIN488.69+1.93 (+0.40%) ▲|LLY1,174.01+14.01 (+1.21%) ▲|LMT533.01-11.50 (-2.11%) ▼|LOW201.48+1.43 (+0.71%) ▲|LRCX287.10-3.10 (-1.07%) ▼|MA589.42+8.32 (+1.43%) ▲|MCD262.52+1.41 (+0.54%) ▲|MDLZ62.37+0.76 (+1.23%) ▲|MDT94.26+2.22 (+2.41%) ▲|META595.84+17.30 (+2.99%) ▲|MMM169.96-0.28 (-0.17%) ▼|MO69.49-0.08 (-0.12%) ▼|MRK150.63+0.77 (+0.51%) ▲|MS213.63+2.59 (+1.23%) ▲|MSFT497.62-3.40 (-0.68%) ▼|MU940.77+7.33 (+0.78%) ▲|NEE82.77-0.16 (-0.19%) ▼|NFLX82.68+1.87 (+2.31%) ▲|NKE38.48+0.36 (+0.94%) ▲|NOW138.12-4.78 (-3.35%) ▼|NVDA226.23+8.79 (+4.04%) ▲|ORCL145.44+4.12 (+2.92%) ▲|PEP141.48+1.69 (+1.21%) ▲|PFE28.86+0.31 (+1.07%) ▲|PG147.58+1.37 (+0.94%) ▲|PLTR170.04-9.88 (-5.49%) ▼|PM188.16+1.01 (+0.54%) ▲|QCOM169.42+2.81 (+1.69%) ▲|RTX202.29-2.87 (-1.40%) ▼|SBUX107.60+1.45 (+1.37%) ▲|SCHW109.43+1.15 (+1.06%) ▲|SO88.02-0.07 (-0.08%) ▼|SPG210.21-1.66 (-0.78%) ▼|T26.36+0.36 (+1.37%) ▲|TMO607.30+6.80 (+1.13%) ▲|TMUS187.48+5.32 (+2.92%) ▲|TSLA355.30-0.79 (-0.22%) ▼|TXN256.70+3.36 (+1.32%) ▲|UBER76.60+1.36 (+1.80%) ▲|UNH400.09+3.79 (+0.96%) ▲|UNP290.67+0.05 (+0.02%) ▲|UPS103.26+0.60 (+0.58%) ▲|USB62.60+1.39 (+2.26%) ▲|V379.26+6.59 (+1.77%) ▲|VZ50.69+0.39 (+0.77%) ▲|WFC89.67+2.63 (+3.02%) ▲|WMT106.05+0.13 (+0.12%) ▲|XOM163.07-1.49 (-0.90%) ▼|
21.3 C
New York
Wednesday, September 2, 2026

Tag: therapy

newssourceFORcompanyinformationcontent1releasesmarket

Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid...

Extended-release buprenorphine (BUP-XR) had lower rates of hospitalizations, emergency department (ED) visits, and outpatient physician office visits compared to those receiving daily oral buprenorphine or no medications for...

The Power of Massage Therapy for Autoimmune Diseases: AMTA Highlights Emerging Research

EVANSTON, Ill., July 23, 2025 /PRNewswire/ -- The American Massage Therapy Association (AMTA) is committed to advancing integrative health care by spotlighting the powerful role...

4TEEN4 Doses First Patient in Phase 1b/2a Trial of Procizumab, a Monoclonal Antibody Targeting the Biological Driver of Shock

Hennigsdorf/ Berlin, July 23, 2025 – 4TEEN4 Pharmaceuticals GmbH today announced that the first patient has been dosed in a Phase 1b/2a PROCARD1 clinical trial evaluating its monoclonal antibody, procizumab, in patients with shock caused primarily by cardiogenic events. Shock is a life-threatening condition characterized by a sudden breakdown in circulatory function due to end-stage disease or acute events, which often leads to organ failure. With only symptomatic treatment options available, shock is associated with a high mortality rate of over 50%. The Phase 1b/2a trial is designed to identify a target dose for procizumab in preparation for further clinical development. In addition, the trial will provide signals of efficacy. In a Phase 1 study in healthy volunteers, procizumab was well tolerated.

Trailhead Biosystems® Expands Human Cell-Based Product Line with iPSC-Derived A9 Dopaminergic Neurons

BEACHWOOD, Ohio, July 23, 2025 /PRNewswire/ -- Trailhead Biosystems, Inc. (TrailBio.com), a biotechnology company pioneering the creation of induced pluripotent stem cell (iPSC)-derived human cells...

Heartflow Plaque Analysis to be Covered by UnitedHealthcare Plans Nationwide

Largest commercial insurer in the United States releases positive comprehensive coverage for AI-enabled Heartflow Plaque Analysis to support precise diagnosis and management of patients 
Largest commercial insurer in the United States releases positive comprehensive coverage for AI-enabled Heartflow Plaque Analysis to support precise diagnosis and management of patients

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025

ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the second quarter of 2025 after the market closes on Tuesday, August 5, 2025.

BD Board Declares Dividend

FRANKLIN LAKES, N.J., July 22, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical...

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 5, 2025 to report its second quarter 2025 financial results and provide a corporate update.

IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC

Clinical efficacy and safety data will be presented from over 70 small-cell lung cancer (SCLC) patients in Hengrui's ongoing, multi-site, open label Phase 1...

Doceree launches co-pay.com, an initiative to build the largest database of co-pay and affordability programs

SHORT HILLS, N.J. , July 22, 2025 /PRNewswire/ -- Doceree, the world's first global network for programmatic HCP engagement, has announced the launch of co-pay.com—the...

Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd

WEXFORD, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, is pleased to announce the extinguishment of its convertible note with YA II PN, Ltd (“Yorkville”).  

Caris Life Sciences Validates and Extends Findings on Tumor-Infiltrating Clonal Hematopoiesis

Validation was shared via a Letter to the Editor in the New England Journal of Medicine IRVING, Texas, July 22, 2025 /PRNewswire/ -- Caris Life...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers